NeuroOne Medical Technologies (NeuroOne Medical Technologies) EBIT : $-12.95 Mil (TTM As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is NeuroOne Medical Technologies EBIT?

NeuroOne Medical Technologies's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-2.89 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-12.95 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NeuroOne Medical Technologies's annualized ROC % for the quarter that ended in Mar. 2024 was -672.92%. NeuroOne Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -705.84%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. NeuroOne Medical Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -56.30%.

NeuroOne Medical Technologies EBIT Historical Data

The historical data trend for NeuroOne Medical Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroOne Medical Technologies EBIT Chart

NeuroOne Medical Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EBIT

Get a 7-Day Free Trial

-6.50

-6.12

-9.95

-10.03

-11.96

NeuroOne Medical Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-3.50	-3.51	-3.17	-3.39	-2.89

Competitive Comparison of NeuroOne Medical Technologies's EBIT

For the Medical Devices subindustry, NeuroOne Medical Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroOne Medical Technologies's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NeuroOne Medical Technologies's EV-to-EBIT falls into.

NeuroOne Medical Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.95 Mil.

NeuroOne Medical Technologies (NAS:NMTC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NeuroOne Medical Technologies's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-11.544 * ( 1 - 0% )	/	( (1.89	+	1.541)	/ 2 )
=	-11.544	/	1.7155
=	-672.92 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.822	-	1.251	-	( 2.681	-	max(0, 1.383	-	5.093	+	2.681	))
=	1.89

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.395	-	1.419	-	( 2.435	-	max(0, 1.54	-	4.71	+	2.435	))
=	1.541

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

NeuroOne Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-11.544	/	( ( (0.645 + max(1.162, 0))	+	(0.607 + max(0.857, 0)) )	/	2 )
=	-11.544	/	( ( 1.807	+	1.464 )	/	2 )
=	-11.544	/	1.6355
=	-705.84 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.543	+	1.609	+	0.26)	-	(1.251	+	0	+	-0.00099999999999989)
=	1.162

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.556	+	1.312	+	0.407)	-	(1.419	+	0	+	-0.00099999999999989)
=	0.857

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NeuroOne Medical Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-12.951	/	23.002
	=	-56.30 %

NeuroOne Medical Technologies EBIT Related Terms

Thank you for viewing the detailed overview of NeuroOne Medical Technologies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroOne Medical Technologies (NeuroOne Medical Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroOne Medical Technologies Corp (NAS:NMTC) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

7599 Anagram Dr., Eden Prairie, MN, USA, 55344

Website

https://www.n1mtc.com

NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

Executives

Mark Christianson	10 percent owner, officer: VP, Business Dev and Marketing	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Ronald W. Mcclurg	officer: Chief Financial Officer	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa	director, officer: CEO and President	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Hijaz Haris	officer: VP of Marketing	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
Morgan C. Frank	10 percent owner	2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907
Manchester Management Co Llc	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02110
Manchester Explorer, L.p.	10 percent owner	MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114
James E Besser	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Manchester Management Pr, Llc	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Edward Andrle	director	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE MN 55344
Wade Fredrickson	10 percent owner	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Steve Mertens	officer: Chief Technology Officer	10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Scott Heuler	officer: Vice President of Sales	10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Paul Buckman	director	12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Suraj Kalia	director	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347